FOLR1 and fallopian tube cancer: On the basis of this observation, the first randomized, multicenter phase III study, FORWARD I (NCT02631876), enrolled platinum-resistant patients (FRα-positive PROC, primary peritoneal or fallopian tube cancer) who have received one to three prior therapies and with high or medium levels of FRα expression, defined as staining intensity ≥2+ in>75% or 50-74% cells, respectively (94).